SUBSCRIBE
SUBSCRIBE
News   Drug Development

Zeltia Group Drug Delays Progression of Ovarian Cancer

September 15, 2008 | 
1 min read

LONDON, Sept 15 (Reuters) - Women with recurrent ovarian cancer given Zeltia’s drug Yondelis in combination with chemotherapy go longer before their disease progresses than those on chemo alone, researchers said on Monday.

Clinical research Phase III Europe
MORE ON THIS TOPIC
Gloved hand holding a vial of mpox vaccine
Vaccines
Bavarian Nordic’s Mpox Shot Shows Antibody Responses Wane After 6 to 12 Months: Study
October 4, 2024
 · 
2 min read
 · 
Tristan Manalac
Podcast
BMS’ Schizophrenia Approval, Pfizer’s Sudden Sickle Cell Withdrawal and Roche’s Pharma Day
October 2, 2024
 · 
1 min read
 · 
Heather McKenzie
3D illustration of human kidneys on a scientific background
Immunology and inflammation
Kezar Reports Four Patient Deaths in Mid-Stage Lupus Nephritis Study, Pauses Enrollment
October 1, 2024
 · 
2 min read
 · 
Tristan Manalac
3D concept photo of gene editing showing a tweezers inserting a DNA fragment into a larger strand
Gene Editing
Gene Editor Prime Medicines Signs BMS Cell Therapy Deal, Reprioritizes Pipeline
September 30, 2024
 · 
2 min read
 · 
Annalee Armstrong